Analysis of Clinical Characteristics and Prognostic Model Construction for Prostate Cancer Patients with a History of Malignancy by Professor Kan Gong ‘s Team | AUA 2024

Analysis of Clinical Characteristics and Prognostic Model Construction for Prostate Cancer Patients with a History of Malignancy by Professor Kan Gong ‘s Team | AUA 2024

With advancements in cancer screening, diagnosis, and treatment, the survival period of cancer patients has significantly increased. Long-term management of cancer patients should not only focus on the primary tumor but also monitor for the occurrence of secondary primary tumors (SPTs) and multiple primary tumors through regular check-ups and screenings. Secondary primary tumors are defined as new independent malignant tumors that arise in different locations following treatment for an initial malignancy, and they are not recurrences or metastases of the first primary tumor. Various factors may contribute to the development of SPTs, such as age, obesity, genetic susceptibility, the stage at diagnosis of the first primary tumor, and environmental exposure. Previous studies have shown that the incidence of SPTs in cancer patients ranges from 8-16%, varying by tumor site . SPTs pose a significant threat to cancer patients' survival, accounting for 55% of cancer-related deaths .
EHA Expert Commentary | Professor Bingcheng Liu: Establishment of a Prognostic Scoring System for Blast Phase Chronic Myeloid Leukemia – Insights from the European Leukemia Network Blast Phase Registry Study

EHA Expert Commentary | Professor Bingcheng Liu: Establishment of a Prognostic Scoring System for Blast Phase Chronic Myeloid Leukemia – Insights from the European Leukemia Network Blast Phase Registry Study

Chronic myeloid leukemia (CML) has a reliable prognostic scoring system during the chronic phase, but blast phase (BP) lacks comprehensive analysis of prognostic factors or standardized scoring systems. Despite the era of tyrosine kinase inhibitors (TKIs), outcomes for BP patients remain poor. From June 13 to 16, 2024, the 29th European Hematology Association (EHA) Annual Congress was held in Madrid, Spain. At the congress, based on data from CML-BP patients diagnosed across multiple countries, the European Leukemia Network established a prognostic scoring system for BP-CML, clearly stratifying CML-BP patients into three distinct survival groups. Hematology Frontier is honored to feature commentary from Professor Bingcheng Liu, Director of the Leukemia Diagnosis and Treatment Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, on this study.
EHA 5-Minute Highlights丨Professor Zonghong Shao: Advances in New Drug Treatments for Myelodysplastic Syndromes (MDS)

EHA 5-Minute Highlights丨Professor Zonghong Shao: Advances in New Drug Treatments for Myelodysplastic Syndromes (MDS)

The treatment journey for Myelodysplastic Syndromes (MDS) is fraught with challenges due to its heterogeneity, hematopoietic failure, complications, and transformation risks, all of which significantly complicate therapy. Notably, the 29th Annual Meeting of the European Hematology Association (EHA 2024), held from June 13 to 16, 2024, showcased significant progress in the field of MDS treatment. In this issue of "Oncology Frontier - Hematology Frontier," we have invited Professor Zonghong Shao from Tianjin Medical University General Hospital to provide an in-depth introduction and commentary on key research in the MDS treatment domain. We hope Professor Shao's insightful sharing will reveal the latest developments in the MDS field, aiding our colleagues in grasping the forefront of treatment and jointly seeking better therapeutic options for MDS patients.
Professor Zhitao Ying: Advances in Diagnosis and Treatment of Mantle Cell Lymphoma | 2024 Nanjing Lymphoma Forum

Professor Zhitao Ying: Advances in Diagnosis and Treatment of Mantle Cell Lymphoma | 2024 Nanjing Lymphoma Forum

Mantle Cell Lymphoma (MCL) is a type of B-cell non-Hodgkin lymphoma (B-NHL) characterized by both the rapid progression of aggressive lymphomas and the incurability of indolent lymphomas, resulting in generally poor prognosis. At the recent "2024 Nanjing Lymphoma Forum," Professor Zhitao Ying from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered an enlightening lecture titled "Advances in Diagnosis and Treatment of Mantle Cell Lymphoma." This article aims to provide a comprehensive overview of the current treatment landscape and emerging strategies for improving outcomes in MCL, as presented by Professor Ying.
Copy of Profound Insights from Professor Xiaofan Zhu on Team’s EHA-Selected Research – Children’s Leukemia

Copy of Profound Insights from Professor Xiaofan Zhu on Team’s EHA-Selected Research – Children’s Leukemia

Currently, the field of pediatric leukemia treatment faces numerous challenges, particularly in predicting relapse risk and developing treatment strategies for relapsed and refractory patients. At the upcoming 29th European Hematology Association (2024 EHA) Annual Meeting, several studies from Professor Xiaofan Zhu’s team from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences have been selected. Two studies on pediatric leukemia delve into these critical issues, providing important academic references for further optimizing pediatric leukemia diagnosis and treatment. To better understand these latest research advances, this issue of "Oncology Frontier - Hematology Frontier" features a detailed interpretation by Professor Xiaofan Zhu.
Copy of ASCO China Voice | Professor Pei Dong Leads Multiple Breakthrough Studies at the ASCO Conference

Copy of ASCO China Voice | Professor Pei Dong Leads Multiple Breakthrough Studies at the ASCO Conference

The 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) was grandly held in Chicago, USA, from May 31 to June 4, 2024. As a premier global event, ASCO gathers oncology experts from around the world to discuss the latest advancements and future trends in the field. At this year's ASCO conference, several studies led by Professor Pei Dong from the Sun Yat-sen University Cancer Prevention and Treatment Center were selected, making a significant impact on the international stage. These studies not only represent new progress in the field of urologic oncology in China but also contribute to the global development of urologic oncology. "Oncology Frontier" has summarized these studies for our readers.
EASL China Voice丨Professor Wei Lu ‘s Team Presents Four Research Findings at EASL 2024

EASL China Voice丨Professor Wei Lu ‘s Team Presents Four Research Findings at EASL 2024

The European Association for the Study of the Liver (EASL) Annual Meeting was successfully held in Milan, Italy, from June 5 to 8, 2024. During the conference, four research posters from Professor Wei Lu 's team at the Hepatobiliary Tumor Department of Tianjin Medical University Cancer Institute and Hospital were presented. These studies cover the fields of liver cancer, cholangiocarcinoma, and liver cirrhosis. This report provides an overview of their findings for our readers.
Crossing Mountains and Seas, Reaching Further—Professor Man Li Shares Highlights of HR+ Advanced Breast Cancer Research at ASCO

Crossing Mountains and Seas, Reaching Further—Professor Man Li Shares Highlights of HR+ Advanced Breast Cancer Research at ASCO

Hormone receptor-positive (HR+) breast cancer accounts for about 70% of all breast cancers. With endocrine therapy as the foundation, chemotherapy, targeted therapy, novel antibody-drug conjugates (ADCs), and immune checkpoint inhibitors (ICIs) provide a wealth of treatment options for HR+ advanced breast cancer patients, also offering more potential combinations for clinical practice. In this "Man Talks Breast Cancer: ASCO Special," Professor Man Li's team from The Second Affiliated Hospital of Dalian Medical University has selected the latest ASCO studies on HR+ advanced breast cancer, covering topics such as cross-line treatment with CDK4/6 inhibitors, novel ADCs combined with ICIs, and comparing CDK4/6 inhibitors + ET with chemotherapy in premenopausal women. These can provide more valuable insights for clinical practice.
Exploring a New Neoadjuvant Strategy with Toripalimab Combined with Chemotherapy to Further Improve Survival Benefits for MIBC Patients

Exploring a New Neoadjuvant Strategy with Toripalimab Combined with Chemotherapy to Further Improve Survival Benefits for MIBC Patients

For patients with muscle-invasive bladder cancer (MIBC), when the tumor is large, deeply invasive, or has local lymph node metastasis, the radicality of whole bladder surgery can be affected. Neoadjuvant therapy can enhance the rate of radical resection by downstaging the tumor, and it has become a current research hotspot. At this year's ASCO Annual Meeting in Chicago, USA, a study led by Professor Hongqian Guo's team from Nanjing Drum Tower Hospital was selected, exploring a new neoadjuvant treatment strategy with toripalimab combined with chemotherapy for MIBC patients. "Oncology Frontier" invited Professor Shun Zhang from Nanjing Drum Tower Hospital to share the relevant content on-site.
Professor Kun Wang: The NeoMDSS Model Accurately Predicts pCR Rates after Neoadjuvant Therapy for Breast Cancer, Enhancing Personalized Treatment

Professor Kun Wang: The NeoMDSS Model Accurately Predicts pCR Rates after Neoadjuvant Therapy for Breast Cancer, Enhancing Personalized Treatment

Breast cancer is a malignant tumor that seriously threatens women's health. Neoadjuvant therapy is a crucial means to provide more surgical opportunities and pave the way for a cure. However, the pathological complete response (pCR) varies significantly with different molecular subtypes and treatment regimens, making it challenging to predict treatment efficacy early in neoadjuvant therapy for individual patients. From May 31 to June 4, 2024, the American Society of Clinical Oncology (ASCO) Annual Meeting was grandly held. At the meeting, Professor Kun Wang's team from Guangdong Provincial People's Hospital presented a study on a model called NeoMDSS, which predicts the effectiveness of neoadjuvant therapy for breast cancer based on MRI and other clinical pathological parameters. Oncology Frontier interviewed Professor Kun Wang to share the main results and clinical significance of this study.